Novel Fluorescent Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida albicans
Open Access
- 1 July 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 39 (7) , 2708-2712
- https://doi.org/10.1128/jcm.39.7.2708-2712.2001
Abstract
A comparative evaluation of the reference National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method with a novel fluorescent carboxyfluorescein diacetate (CFDA)-modified microdilution method for the susceptibility testing of fluconazole was conducted with 68 Candida strains, including 53 Candida albicans , 5 Candida tropicalis , 5 Candida glabrata , and 5 Candida parapsilosis strains. We found trailing endpoints and discordant fluconazole MICs of C. albicans strains. These strains satisfy the definition of the low-high MIC phenotype. All 12 low-high phenotype strains were correctly shown to be susceptible at 48 h with the CFDA-modified microdilution method. For the 41 non-low-high phenotype C. albicans strains, the CFDA-modified microdilution method yielded 97.6% (40 of 41 strains) agreement within ±1 dilution at 24 h compared with the reference method and 92.7% (38 of 41 strains) agreement within ±1 dilution at 48 h compared with the reference method. The five strains each from C. tropicalis , C. glabrata, and C. parapsilosis that were tested showed 100% agreement within ±2 dilutions for the two methods being evaluated.Keywords
This publication has 23 references indexed in Scilit:
- Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998Antimicrobial Agents and Chemotherapy, 2000
- International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal InfectionsClinical Infectious Diseases, 1997
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986–April 1996, issued May 1996American Journal of Infection Control, 1996
- Trends and sources of nosocomial fungaemiaMycoses, 1994
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993
- Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeastsAntimicrobial Agents and Chemotherapy, 1993
- Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989The American Journal of Medicine, 1991
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of internal medicine (1960), 1988
- Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importanceJournal of Antimicrobial Chemotherapy, 1980